Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Bristol Myers Squibb

Biotech buyout: San Diego's Turning Point Therapeutics sells to Bristol Myers Squibb for $4.1 billion

Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.

Tribune News Service

40 Stocks Moving In Friday's Mid-Day Session

40 Stocks Moving In Friday's Mid-Day Session

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.

Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead?

Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead?

Turning Point Therapeutics snagged a $4.1 billion offer from Bristol Myers Squibb on Friday, and TPTX stock more than doubled.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology

BridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. Under the agreement terms, BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in…

Immatics Initiates Phase 1 Clinical Trial of IMA401 in Advanced Solid Tumors

Immatics N.V. (NASDAQ: IMTX) announced the initiation of a Phase 1 clinical trial of its drug candidate IMA401 for patients with recurrent and/or refractory solid tumors.

Top Funds Bet On These Stocks To Rise From Down Market

Led with a more-than $3 billion bet on Apple, the best mutual funds continue to invest heavily during this market correction.

Investors Business Daily

Bristol Myers Takes Machete To 2022 Outlook As Generics Slam Revlimid, Abraxane

Bristol Myers Squibb cut its 2022 guidance Friday amid patent losses and Revlimid erosion. In response, BMY stock tumbled.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

U.S. FDA Approves Bristol Myers Squibb's Camzyos™ (mavacamten) for the Treatment of Adults With obstructive HCM

U.S. FDA Approves Bristol Myers Squibb's Camzyos™ (mavacamten) for the Treatment of Adults With obstructive HCM

Bristol Myers Squibb (NYSE: BMY) announced the U.S.

MindMed Appoints Francois Lilienthal As New CCO

MindMed Appoints Francois Lilienthal As New CCO

With over twenty years of experience in the biopharmaceutical industry, Francois Lilienthal, MD, has joined Mind Medicine Inc. (NASDAQ:MNMD) as chief commercial officer (CCO). He had been serving as a consultant for the company for the last six months. Lilienthal has a long trajectory with pharmaceutical companies—in 1997, he was…

Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents

Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents

Bristol Myers Squibb Co (NYSE: BMY) claims that AstraZeneca Plc's (NASDAQ: AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint.

Pfizer's Newest Way To Rival Bristol Myers Squibb Might Surprise You

Pfizer's Newest Way To Rival Bristol Myers Squibb Might Surprise You

Pfizer stock rose near its 50-day line Friday after the drug giant wrapped its $6.7 billion takeover of biotech Arena Pharmaceuticals.

Investors Business Daily

Bristol Myers Squibb is Soaring, and the Stock is Still Cheap

Bristol Myers Squibb is Soaring, and the Stock is Still Cheap

Bristol Myers Squibb's (BMY) outstanding clinical and operational performance, as well as the current momentum across its product portfolio, have enabled the biopharmaceutical concern to post stable revenue growth in its most recent quarterly earnings release. In addition, the stock is currently trading at a discounted valuation despite generating substantial…

CTI BioPharma's Bone Marrow Cancer Drug Scores FDA Approval

CTI BioPharma's Bone Marrow Cancer Drug Scores FDA Approval

The FDA approved CTI BioPharma Corp's (NASDAQ:CTIC) Vonjo (pacritinib) for treating adult patients with myelofibrosis, a type of bone marrow cancer with low blood platelets count. Pacritinib is a JAK inhibitor and will compete with Incyte Corporation's (NASDAQ:INCY) Jakafi and Bristol Myers Squibb's Co (NYSE:BMY) Inrebic, which were approved in 2011 and 2019, respectively for myelofibrosis. CTI…

Drug Giant Bristol Myers Squibb Stock Sees Composite Rating Climb To 96

Drug Giant Bristol Myers Squibb Stock Sees Composite Rating Climb To 96

Bristol Myers Squibb saw an improvement in its IBD SmartSelect Composite Rating Friday, from 94 to 96.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Bristol Myers Squibb's Mavacamten Aces Late-Stage Trial In Cardiomyopathy

Bristol Myers Squibb Co's (NYSE: BMY) VALOR-HCM Phase 3 study evaluating mavacamten in adults with obstructive hypertrophic cardiomyopathy (obstructive HCM)

3 Warren Buffett Stocks to Buy in February: DaVita, Bristol Myers Squibb, and AbbVie

Warren Buffett’s value investing strategy has paid off, as its investment firm Berkshire Hathaway (BRK.A) has outperformed the broader market. Recently, the billionaire has become worther than Meta Platforms (FB) founder Mark Zuckerberg. Hence, we believe that the Berkshire Hathaway holdings AbbVie (ABBV), Bristol-Myers Squibb (BMY), and DaVita (DVA) might…

1 2 3

People

Mark Zuckerberg

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Berkshire Hathaway

Bristol Myers Squibb

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

239,511 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play